Nasdaq4d
COSCIENS Biopharma Initiates Phase 2a Clinical Efficacy Study for Avenanthramides Product Following Successful Phase 1 Safety Results
COSCIENS aims to leverage this research to explore potential commercialization opportunities, emphasizing the transformative potential of their avenanthramide product for cardiovascular health and ...
Nasdaq4d
COSCIENS Biopharma Advances Avenanthramide Clinical Trial To Phase 2a For Inflammation Treatment
(RTTNews) - COSCIENS Biopharma Inc. (CSCI) has initiated the Phase 2a clinical efficacy study of its avenanthramide product, aimed at managing inflammation-related conditions. Avenanthramides ...
Cosciens Biopharma announces initiation of Phase 2a study for avenanthramides
COSCIENS Biopharma (CSCI)announced initiation of its Phase 2a clinical efficacy study of its flagship avenanthramides product being developed ...
Investing4d
COSCIENS advances to Phase 2a study for inflammation treatment
The Phase 1 trial, part of the AvenActive study, was a placebo-controlled, randomized, adaptive study to assess the safety, tolerability, and pharmacokinetics of the avenanthramide product.
Investing4d
COSCIENS advances to Phase 2a study for inflammation treatment
TORONTO - COSCIENS Biopharma Inc. (NASDAQ: CSCI) (TSX: CSCI), a developer of health and wellness products currently trading at $2.69, has announced the initiation of the Phase 2a clinical efficacy ...